Growth in cell & gene therapy manufacturing services market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs.
However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of cell & gene therapy manufacturing services market to a certain extent.
The pandemic slowed the economic growth of various countries, including the US, Germany, the UK, India, and China. It also resulted in control measures that impacted operations in life science organizations, such as production and research.
For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441
According to GEP Worldwide, more than 1,200 clinical trials across the globe were disrupted by June 2020. Nearly 61% of clinical trials were disrupted due to the suspension of patient enrolment. The impact varied due to changes in COVID-19 case volumes throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory disease, oncology, ID/anti-infectives, and cardiovascular disease were the worst-hit during this time.
The increase in pharmaceutical R&D has resulted in a sharp increase in the number of cell & gene therapy candidates under development. This has made it necessary to outsource manufacturing services to develop cost-effective and efficient cell & gene therapies.
The cost of manufacturing for gene therapy can be between USD 500,000 and USD 1 million, excluding the costs for R&D, the costs to run crucial clinical trials, or the costs to build the commercial infrastructure necessary to provide access to patients.
According to a 2020 PhRMA report on the cell & gene therapy pipeline in 2018, there were 289 cell & gene therapies in clinical development by biopharmaceutical companies. This number increased by 25% in 2020, with 362 cell & gene therapies in clinical development.
The Cell & Gene Therapy Manufacturing Services Market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2020, the pharmaceutical & biotechnology companies segment is expected to register the highest CAGR during the forecast period.
